BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ala M. Target c-Myc to treat pancreatic cancer. Cancer Biol Ther 2022;:1-17. [PMID: 34978469 DOI: 10.1080/15384047.2021.2017223] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Jandova J, Galons JP, Dettman DL, Wondrak GT. Systemic deuteration of SCID mice using the water-isotopologue deuterium oxide (D(2) O) inhibits tumor growth in an orthotopic bioluminescent model of human pancreatic ductal adenocarcinoma. Mol Carcinog 2023. [PMID: 36727657 DOI: 10.1002/mc.23509] [Reference Citation Analysis]
2 Feng H, Tan J, Wang Q, Zhou T, Li L, Sun D, Fan M, Cheng H, Shen W. α-hederin regulates glucose metabolism in intestinal epithelial cells by increasing SNX10 expression. Phytomedicine 2023;111:154677. [PMID: 36724620 DOI: 10.1016/j.phymed.2023.154677] [Reference Citation Analysis]
3 Li K, Huo Q, Li B, Yokota H. The Double-Edged Proteins in Cancer Proteomes and the Generation of Induced Tumor-Suppressing Cells (iTSCs). Proteomes 2023;11:5. [DOI: 10.3390/proteomes11010005] [Reference Citation Analysis]
4 Benito-Lopez JJ, Marroquin-Muciño M, Perez-Medina M, Chavez-Dominguez R, Aguilar-Cazares D, Galicia-Velasco M, Lopez-Gonzalez JS. Partners in crime: The feedback loop between metabolic reprogramming and immune checkpoints in the tumor microenvironment. Front Oncol 2022;12:1101503. [PMID: 36713558 DOI: 10.3389/fonc.2022.1101503] [Reference Citation Analysis]
5 Liu S, Qin Z, Mao Y, Zhang W, Wang Y, Jia L, Peng X. Therapeutic Targeting of MYC in Head and Neck Squamous Cell Carcinoma. OncoImmunology 2022;11:2130583. [DOI: 10.1080/2162402x.2022.2130583] [Reference Citation Analysis]
6 Valiuska S, Psaras AM, Noé V, Brooks TA, Ciudad CJ. Targeting MYC Regulation with Polypurine Reverse Hoogsteen Oligonucleotides. Int J Mol Sci 2022;24. [PMID: 36613820 DOI: 10.3390/ijms24010378] [Reference Citation Analysis]
7 Mugiyanto E, Adikusuma W, Irham LM, Huang W, Chang W, Kuo C. Integrated genomic analysis to identify druggable targets for pancreatic cancer. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.989077] [Reference Citation Analysis]
8 Dutta M, Mohapatra D, Mohapatra AP, Senapati S, Roychowdhury A. ATAD2 suppression enhances the combinatorial effect of gemcitabine and radiation in pancreatic cancer cells. Biochemical and Biophysical Research Communications 2022;635:179-186. [DOI: 10.1016/j.bbrc.2022.10.021] [Reference Citation Analysis]
9 Sequera C, Grattarola M, Holczbauer A, Dono R, Pizzimenti S, Barrera G, Wangensteen KJ, Maina F. MYC and MET cooperatively drive hepatocellular carcinoma with distinct molecular traits and vulnerabilities. Cell Death Dis 2022;13:994. [PMID: 36433941 DOI: 10.1038/s41419-022-05411-6] [Reference Citation Analysis]
10 Zhang W, Li S, Li C, Li T, Huang Y. Remodeling tumor microenvironment with natural products to overcome drug resistance. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1051998] [Reference Citation Analysis]
11 Romeo MA, Gilardini Montani MS, Arena A, Benedetti R, D'Orazi G, Cirone M. c-Myc Sustains Pancreatic Cancer Cell Survival and mutp53 Stability through the Mevalonate Pathway. Biomedicines 2022;10:2489. [PMID: 36289751 DOI: 10.3390/biomedicines10102489] [Reference Citation Analysis]
12 Liu Y, Vandekeere A, Xu M, Altea-manzano P, Fendt S. Metabolite-derived protein modifications modulating oncogenic signaling. Front Oncol 2022;12:988626. [DOI: 10.3389/fonc.2022.988626] [Reference Citation Analysis]
13 Marconi GD, Della Rocca Y, Fonticoli L, Melfi F, Rajan TS, Carradori S, Pizzicannella J, Trubiani O, Diomede F. C-Myc Expression in Oral Squamous Cell Carcinoma: Molecular Mechanisms in Cell Survival and Cancer Progression. Pharmaceuticals 2022;15:890. [DOI: 10.3390/ph15070890] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Hung YH, Chen LT, Hung WC. The Trinity: Interplay among Cancer Cells, Fibroblasts, and Immune Cells in Pancreatic Cancer and Implication of CD8+ T Cell-Orientated Therapy. Biomedicines 2022;10:926. [PMID: 35453676 DOI: 10.3390/biomedicines10040926] [Reference Citation Analysis]